Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytokinetics, Incorporated - Common Stock (NQ: CYTK )

46.16 +4.54 (+10.91%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,821,321
Open 41.54
Bid (Size) 45.55 (4)
Ask (Size) 46.48 (25)
Prev. Close 41.62
Today's Range 40.77 - 46.26
52wk Range 40.53 - 81.36
Shares Outstanding 95,640,600
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MGM Resorts To Rally Around 75%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Via Benzinga

Performance

YTD
-5.66%
-5.66%
1 Month
-1.77%
-1.77%
3 Month
-11.13%
-11.13%
6 Month
-18.24%
-18.24%
1 Year
-39.97%
-39.97%

More News

Read More
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
Via Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Why Cytokinetics Stock Was a Nearly 5% Winner Today
Via The Motley Fool
Peering Into Cytokinetics's Recent Short Interest
Via Benzinga
This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Via Benzinga
Netflix To $650? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Via MarketBeat
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Via Investor's Business Daily
Cytokinetics Sets Stage For Mid-Stage Study For Heart Failure Drug After Encouraging Data From Phase 1 Study
Via Benzinga
CYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
Via Investor's Business Daily
7 Biotech Stocks to Boost Your Portfolio to Peak Health
Via InvestorPlace
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Via InvestorPlace
Dow Dips Over 550 Points; BJ's Wholesale Club Earnings Beat Views
Via Benzinga
Topics Earnings Stocks
Exposures Financial US Equities
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stocks Mixed Amid Flood Of Economic Data
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Gold Falls Sharply; US Composite PMI Surges In May
Via Benzinga
Why Cytokinetics (CYTK) Shares Are Falling
Via Benzinga
Why NVIDIA Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
NVIDIA To Rally Over 39%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.